Menu
Not yet recruiting NCT06977373

The Application Value of Spectral CT in the Accurate Staging of Colorectal Cancer

No phase Interventional Colorectal Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: To explore the value of spectral CT in the diagnosis and treatment of colorectal cancer.
Who it may be relevant to
Registry conditions: Colorectal Cancer. Basic parameters: 18 years — 90 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

Spectral CT was used to prospectively collect medical images and clinical data related to colorectal cancer, evaluate the effect of image quality in the diagnosis of colorectal cancer, and evaluate the application value in the accurate staging of colorectal cancer, so as to provide a more accurate clinical basis for diagnosis, promote the development of individualized treatment, and ultimately improve the prognosis of patients.

Interventions

  • Diagnostic test To explore the value of spectral CT in the diagnosis and treatment of colorectal cancer
    The CT scan is part of the standard treatment protocol.

Primary outcome measures

  • Pathological TNM staging [Time frame: 1 day]

Eligibility criteria

Inclusion criteria

  • Undergo a contrast-enhanced Quark Spectral CT scan of the lower abdomen/pelvis within 1 week before treatment.
  • Age > 18 years.
  • Patients suspected of having colorectal cancer.
  • Patients who have signed the informed consent form.

Exclusion criteria

  • Severe cardiac, pulmonary, or renal insufficiency.
  • Allergy to iodine-based contrast agents.
  • Inability to cooperate with the CT examination.
  • Poor image quality of the Quark Spectral CT scan.
  • Women who are pregnant or breastfeeding.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Diagnostic

Study locations

China · 1 center
  • Yunnan Cancer Hospital — Kunming

Identifiers

NCT: NCT06977373 · KYLX2025-101

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗